Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salbutamol Nebulization via HFNC in COPD Exacerbation
NCT03449056Phase 3Unknown
- Sponsor
- CHU de Poitiers
- Start
- Jan 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of salbutamol in chronic obstructive pulmonary disease (COPD), sponsored by CHU de Poitiers. Primary endpoint: Lung functions at 1.5 hours. Status: unknown.
02
Drugs
salbutamol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03449056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03449056.